NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
The private stem cell bank Cellaviva, which is owned by NextCell, has been licensed from the Swedish Health Authority (IVO) to operate a tissue facility in Sweden since 2014, which is a regulatory requirement to handle this type of product. Logistics, distribution, and warehousing are core business activities for Cellaviva, and Tience is a welcome source of income that generates profit from the start, regardless of the strength of sales. The great interest in this type of product could soon provide Cellaviva with significant revenue in variable remuneration.
"The Swedish market is very important to Linio and we have a waiting list of clinics that hope to gain access to Tience already this year. NextCell and Cellaviva were an obvious choice for us as partners, with almost 10 years of experience in operating tissue facilities," says Karita Reijonsaari, CEO at Linio Biotech.
More information about Linio Biotech and the product Tience can be found at https://www.linio-biotech.com/
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, info@fnca.se.
About NextCell Pharma AB
NextCell is a cell therapy company in phase II trails with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trails for COVID-19, in Örebro and in Montreal, Canada. The company is in the process of establishing its own GMP-facality for the production of ProTrans. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.